A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Participant must be Caucasian * Body mass index (BMI) within the range of 19.0 to 32.0 kilograms per meter squared (kg/m²) Exclusion Criteria: * Have known allergies to selpercatinib-related compounds or any components of the formulation of selpercatinib, or or rosuvastatin * • Have a significant previous or current history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product * Have used or are intending to use over-the-counter or prescription medication, including dietary supplements and herbal medications, within 14 days prior to dosing